NAVERIS, a company focused on technological innovations in cancer detection and drug development, recently announced a successful funding round, raising $17,400,000. The funding will be used to further develop their cutting-edge technologies aimed at revolutionizing cancer detection, drug development, and clinical trials. Their primary focus lies in the development of a liquid biopsy blood test that can detect specific subtypes of cancer by analyzing tumor DNA in the circulation. This groundbreaking technology shows promise in detecting cancers at an early stage, months before patients would typically exhibit symptoms. The company's mission to bring advancements in cancer diagnostics and treatment underscores the importance of early detection in ensuring more favorable outcomes for patients. The recent funding injection will undoubtedly propel NAVERIS closer to achieving its goal of transforming cancer care through innovative technologies.








